ESC recommends treating all AF patients over 75 years old with Vitamin K antagonist or new oral anticoagulation treatments because of the benefit on ischemic events. The challenge is to deal with hemorrhagic risk which should be carefully evaluated. It increases in case of renal disturbance and low weight, especially with new oral anticoagulation therapy.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.